

## RAPID COMMUNICATION

# Corticotropin-releasing hormone stimulates NF- $\kappa$ B in human epidermal keratinocytes

Blazej Zbytek<sup>1,2</sup>, Lawrence M Pfeffer<sup>1</sup> and Andrzej T Slominski<sup>1</sup>

<sup>1</sup>Department of Pathology and Laboratory Medicine, University of Tennessee Health Science Center, Memphis, TN, USA

<sup>2</sup>Department of Histology and Immunology, Medical University of Gdansk, Gdansk, Poland

(Requests for offprints should be addressed to A Slominski; Email: aslominski@utmem.edu)

### Abstract

Corticotropin-releasing hormone (CRH) has been shown to inhibit proliferation and modulate expression of inflammation markers in the epidermal cells. In the present study we report that CRH also stimulates nuclear factor-kappa B (NF- $\kappa$ B) activity. Incubation with CRH of human keratinocytes derived from primary cultures resulted in increased binding of DNA by NF- $\kappa$ B. CRH induced translocation of NF- $\kappa$ B subunit p65 from the cytoplasm to the nucleus and induced expression of  $\kappa$ B-driven chloramphenicol acetyltransferase (CAT)

reporter gene. NF- $\kappa$ B translocation was accompanied by degradation of the inhibitor of NF- $\kappa$ B  $\alpha$  (I $\kappa$ B- $\alpha$ ). Specificity of the CRH effect was demonstrated by the use of CRH-R antagonists antalarmin and  $\alpha$ -helical CRH [9–41]. CRH-dependent stimulation of NF- $\kappa$ B activity is consistent with accumulated data about role of this neuropeptide in the regulation of local epidermal homeostasis.

*Journal of Endocrinology* (2004) **181**, R1–R7

### Introduction

Keratinocytes not only are the main building blocks of the epidermis, but also are regulators of the plentitude of local epidermal processes (reviewed in: Barker *et al.* 1991). Their role in immune reactions may involve constitutive expression of Toll-like receptors (Mempel *et al.* 2003), or regulated expression of cytokines and cytokine receptors, major histocompatibility complex II antigens and adhesion molecules (reviewed in: Barker *et al.* 1991, Freedberg *et al.* 2001). Keratinocytes express receptors to various neurotransmitters including catecholamines (reviewed in: Schallreuter 1997). Lastly, keratinocytes produce hormones and express corresponding receptors including effectors of the hypothalamo-pituitary-adrenal axis (reviewed in: Slominski *et al.* 2000c, 2001, Slominski & Wortsman 2000).

Corticotropin-releasing hormone has a major role in coordinating the cellular stress response (Chrousos & Gold 1992). CRH not only stimulates secretion of pro-opiomelanocortin (POMC)-derived peptides by corticotrophes, but also modulates the phenotype of many cell types. CRH actions in the immune system include induction of degranulation of mast cells, increased expression of interleukin (IL) 2 receptor and stimulation of lymphocyte

proliferation (Singh 1989, Theoharides *et al.* 1998). CRH-dependent production of IL-1 and IL-6 by leukocytes varies depending on activation status of these cells (Hagan *et al.* 1991, Leu & Singh 1992, Pereda *et al.* 1995, Singh & Leu 1990).

CRH is also produced locally in peripheral organs including the skin to regulate local homeostasis (Slominski *et al.* 1998, 2000b, 2000c 2001). Human keratinocytes express several isoforms of CRH receptor type 1 (CRH-R1) (Pisarchik & Slominski 2001, Slominski *et al.* 2001). CRH inhibits proliferation of both human primary and immortalized keratinocytes (Quevedo *et al.* 2001, Slominski *et al.* 2000a). CRH increases cyclic adenosine monophosphate (cAMP) production levels in immortalized keratinocytes (Slominski *et al.* 2000a) and calcium levels in both immortalized and human primary keratinocytes (Fazal *et al.* 1998, Slominski *et al.* 1999, Wiesner *et al.* 2002). CRH increases production of IL-6 and IL-11 in immortalized keratinocytes and increases both human leukocyte antigen DR (HLA-DR) and intercellular adhesion molecule 1 (ICAM-1) expression in human primary keratinocytes (Quevedo *et al.* 2001, Zbytek *et al.* 2002).

Inflammation and proliferation remain under the control of a plethora of transcription factors, with NF- $\kappa$ B

considered to play an important role (reviewed in: Li & Verma 2002). NF- $\kappa$ B activation is stimulated by many pathways that converge on I $\kappa$ B kinases including the signaling pathways activated by lipopolysaccharide, tumor necrosis factor  $\alpha$  (TNF- $\alpha$ ) and T-cell receptor signaling. Phosphorylation and subsequent degradation of I $\kappa$ B proteins allow for release and then translocation of NF- $\kappa$ B to the nucleus, where it can bind to transcription-regulatory sequences to activate specific genes (Li & Verma 2002). CRH was found to stimulate NF- $\kappa$ B activity in mouse thymocytes (Zhao & Karalis 2002). In corticotrophic AtT20 cells, CRH suppressed NF- $\kappa$ B activity induced by hydrogen peroxide treatment (Lezoualc'h *et al.* 2000). In immortalized HaCaT keratinocytes CRH attenuated NF- $\kappa$ B activity that had been increased by removal of growth factors (Zbytek *et al.* 2003).

To further characterize the physiological role of CRH in the epidermis we examined the effects of CRH on human adult primary keratinocytes.

## Materials and Methods

### Cell culture

Human epidermal keratinocytes derived from adult skin were cultured in Epilife medium (containing bovine serum albumin (BSA), bovine transferrin, hydrocortisone, recombinant human insulin-like growth factor type-1, prostaglandin E<sub>2</sub>, recombinant human epidermal growth factor, penicillin G (100 U/ml), streptomycin (100  $\mu$ g/ml), amphotericin B (0.25  $\mu$ g/ml) and calcium at 0.06 mM, Cascade Biologics, Inc., Portland, OR).

Cells from the third or fourth passage were seeded at density 10,000 cells/cm<sup>2</sup> and grown for 48 h before addition of CRH to final concentration of 1 or 100 nM (Molecular Research Lab, NC), phorbol 12-myristate 13-acetate (PMA, 100 nM, Sigma, St Louis, MO) or interferon  $\gamma$  (1000 U/ml, Biosource, Camarillo, CA).

### Electrophoretic mobility shift assay

Nuclei extracts were prepared as previously described (Yang *et al.* 2000) and were used for electrophoretic mobility shift assay (EMSAs). A NF- $\kappa$ B oligonucleotide probe (Promega, Madison, WI) was end-labeled with [ $\gamma$ -<sup>32</sup>P] deoxy-ATP using T4 polynucleotide kinase. Binding reaction consisted of 5  $\mu$ g of nuclear extract, ~0.05 pM of NF- $\kappa$ B oligonucleotide probe, 1  $\mu$ g of double strand poly(dI)•poly(dC), 5  $\mu$ l of 5X incubation buffer (10 mM Tris-HCl, pH=7.5, 1 mM EDTA, pH=8, 40 mM NaCl, 4% v/v glycerol, 0.008% v/v  $\beta$ -mercaptoethanol) and water in a final volume of 25  $\mu$ l. The protein-DNA complexes were separated on 5% polyacrylamide gel. For supershift assays nuclear extracts were incubated with antibodies (0.2  $\mu$ g per assay) to either p50 (sc-1190), p65 (sc-109), c-rel (sc-70) or p52 (sc-298)

(Santa Cruz Biotechnology Inc., Santa Cruz, CA). To determine binding specificity, a 50x excess of unlabelled oligonucleotide was used. Radioactivity was quantitated with Packard Cyclone phosphorimager, and analyzed with Optiquant (Perkin-Elmer Life Sciences Inc., Boston, MA) and Adobe Photoshop (San Jose, CA) software.

### Reporter gene assay


Keratinocytes were transfected using Lipofectamine Plus reagent (Gibco, Invitrogen Life Technologies, Carlsbad, CA) with either the pUX-CAT promoterless chloramphenicol acetyltransferase construct or pUX-CAT 3 XHLA $\kappa$ B construct, which contains three tandemly repeated copies of NF- $\kappa$ B site from HLA-B7 gene (provided by Dr. J. Vilcek, New York University Medical Center). To demonstrate the specificity of CRH action, 1 h before addition of CRH, either CRH-R non-peptide antagonist antalarmin (10  $\mu$ M, Sigma, St Louis, MO) or peptide antagonist  $\alpha$ -helical CRH [9–41] (10  $\mu$ M, Sigma, St Louis, MO) was added. CAT activity was assayed by thin layer chromatography and quantitated by phosphorimaging using Optiquant software (Packard Cyclone, Perkin-Elmer Life Sciences Inc., Boston, MA) and normalized to expression of pSV- $\beta$ -galactosidase control vector (Promega, Madison, WI).

### Immunolocalization of p65 in epidermal cells (confocal laser microscopy)

Cells were seeded in 8 well Lab-Tek II chamber slides (Nalge Nunc, Inc., Naperville, IL). Subconfluent cells were stimulated with 100 nM CRH for 60 min and fixed with 4% paraformaldehyde (in phosphate buffered saline (PBS)) for 10 min. The cells were permeabilized with 0.1% Triton X-100 (in PBS) for 5 min and blocked with 1% BSA (in PBS) for 30 min. Then cells were stained consecutively with rabbit primary anti-human p65 antibody (sc-372) for 1 h (Santa Cruz Biotechnology, Inc., Santa Cruz, CA), anti-rabbit streptavidin conjugate for 1 h and FITC-avidin conjugate (Vector Laboratories, Inc., Burlingame, CA) for 30 min in buffer containing 0.1% Triton X-100, 1% BSA in PBS. The slides were extensively washed with PBS between stainings, and then mounted with Vectashield mounting medium (Vector Laboratories, Inc., Burlingame, CA). Slides not stained with primary antibody were used as background controls. Slides were observed with laser scanning confocal fluorescent microscope (LSM 510, Carl Zeiss GmbH, Jena, Germany). Plan-Neofluor oil immersion 40x objective, excitation wavelength 488 nm and long pass filter 560 nm were used and 0.47  $\mu$ m optical sections were generated.

### Western blot analysis of I $\kappa$ B- $\alpha$

Cells were lysed in RIPA buffer and clarified by centrifugation (10,000 g, 10 min). Cell lysates (10  $\mu$ g) were



**Figure 1** CRH treatment increases NF- $\kappa$ B DNA binding activity in the keratinocytes. Nuclear extracts were prepared from cells grown in EpiLife medium and stimulated with CRH for indicated time periods. Nuclear extracts were subjected to EMSA. (A) 100 nM CRH increased NF- $\kappa$ B DNA binding activity at the time-dependent manner. The activity increased at 15 min to reach maximum at 60 min. (B) At 60 min incubation CRH did not modify the NF- $\kappa$ B binding activity induced by interferon  $\gamma$  (IFN  $\gamma$ ) and PMA. Stimulatory effect of CRH was evident at 100 nM but not at 1 nM concentration. (C) Nuclear extracts obtained after 60 min incubation with CRH (control) were subjected to supershift assays with a panel of antibodies directed against various components (p52, c-rel, p65, p50) of NF- $\kappa$ B dimers. Cold represents nuclear extract pre-incubated with 50x excess of unlabelled oligonucleotide. Arrows denote protein-DNA or antibody-protein-DNA complexes. Results are representative of two separate experiments.

separated on 12% SDS-PAGE gel and transferred to the PVDF membrane. After blocking with Tris buffered saline, 0.05% Triton X-100 and 5% milk, the membranes were incubated with rabbit anti-human I $\kappa$ B- $\alpha$  affinity-purified polyclonal IgG (sc-371, 1:200, Santa Cruz Biotechnology Inc., Santa Cruz, CA), followed by incubation with horseradish peroxidase conjugated goat anti-rabbit IgG (1:10000). I $\kappa$ B- $\alpha$  was visualized with Supersignal West Pico Chemiluminescent Substrate (Pierce, Rockford, IL). The membranes were stripped and re-probed with antibody against actin (1:500, Santa Cruz Biotechnology Inc., Santa Cruz, CA). The chemiluminescent signal was acquired on a Fluor-S MultiImager and analyzed with Quantity One software (Bio-Rad Laboratories, Hercules, CA).

#### Statistical analysis

Values are presented as means  $\pm$  S.E.M. Significance between test groups was determined by ANOVA and Tukey's multiple comparison post-hoc test using Prism 4.00 software (GraphPad Software, San Diego, CA).

## Results


### CRH stimulates NF- $\kappa$ B DNA binding activity in the keratinocytes

Human primary keratinocytes were grown in supplemented EpiLife medium and then stimulated with

100 nM CRH for 15, 30, 60 and 120 min. After stimulation with CRH, nuclear extracts were prepared and analyzed for NF- $\kappa$ B activation by EMSA (Fig. 1A). CRH induced NF- $\kappa$ B DNA binding activity at 15 min incubation and DNA binding further increased to reach maximum at 60 min incubation. NF- $\kappa$ B DNA binding activity returned to near the basal level at 120 min after CRH addition. The effect of CRH was dose dependent, i.e., was observed at 100 nM CRH and absent at 1 nM CRH (Fig. 1B). As shown in Fig. 1, two CRH-induced NF- $\kappa$ B complexes were observed. In order to determine the composition of CRH-induced NF- $\kappa$ B complexes, nuclear extracts were preincubated with antibodies to specific Rel proteins and analyzed by supershift assays (Fig. 1C). It was determined that, while the lower CRH-induced complex contains both p50 and a p65 protein, the upper complex only contains p50.

### CRH induces $\kappa$ B-driven reporter gene activity in the keratinocytes

In order to determine whether increase in NF- $\kappa$ B DNA binding activity has functional consequences in the keratinocytes, we performed gene reporter assays with a CAT construct driven by the  $\kappa$ B site derived from HLA-B7 gene. As shown in Fig. 2, incubation of transiently transfected keratinocytes with CRH increased CAT



<b>promoterless construct</b>	+		+		-		-		-
<b>NF-<math>\kappa</math>B dependent construct</b>	-		-		+		+		+
<b>CRH</b>	-		+		-		+		+
<b><math>\alpha</math>-helical CRH [9-41]</b>	-		-		-		-		+
<b>Antalarmin</b>			-		-		-		+

**Figure 2** CRH increases NF- $\kappa$ B-dependent transcriptional activity in keratinocytes. Keratinocytes were transiently transfected with pUX-CAT (construct without  $\kappa$ B site) or pUX-CAT 3 XHLA $\kappa$ B (construct containing  $\kappa$ B site) vector, incubated for 60 min without (untreated) or with 100 nM CRH, in the absence and presence of CRH-R antagonists (antalarmin and  $\alpha$ -helical CRH [9-41]), and assayed for CAT activity. The data represents a representative of three experiments performed in triplicate and values are presented as means  $\pm$  S.E.M. after subtraction of background, related to activity of the construct without  $\kappa$ B site (=1). \* $P$  < 0.001 between control (no treatment) and CRH treatment. # $P$  < 0.001 between CRH treatment and CRH treatment in the presence of antagonists.

activity by 4.4-fold. Preincubation of cells for 1 h with both non-peptide (antalarmin) and peptide ( $\alpha$ -helical CRH [9-41]) CRH antagonists significantly attenuated the CRH-induced signal. In contrast, CRH had no significant effect on the promoterless construct, which demonstrated that observed effects are  $\kappa$ B-dependent.

#### CRH induces p65 translocation in keratinocytes


To further characterize the activation of NF- $\kappa$ B by CRH, we examined the cellular localization of the p65 protein in the keratinocytes by confocal microscopy. The p65 protein was detected in CRH-induced complexes by gel shift assays. In normal human keratinocytes, p65 is localized mainly in the cytoplasm with little nuclear staining

detectable. Treatment with 100 nM CRH for 60 min induced translocation of p65 antigen from the cytoplasm into the nucleus. At 120 min incubation p65 was localized predominantly in the cytoplasm (Fig. 3). The transient translocation of p65 into the nucleus closely parallels its appearance in nuclear extracts as determined in gel shift assays (Fig. 1).

#### Western blot for I $\kappa$ B- $\alpha$

Inhibitory I $\kappa$ B proteins sequester NF- $\kappa$ B in the cytoplasm and tightly control the activity of NF- $\kappa$ B. Phosphorylation, ubiquitination and degradation of I $\kappa$ B proteins precedes NF- $\kappa$ B release and translocation to the nucleus (Li & Verma 2002). To determine whether NF- $\kappa$ B





**Figure 3** CRH induces p65 translocation from the cytoplasm to the nucleus. Keratinocytes were grown on 8 well chamber slides in growth media. 100 nM CRH was added for 60 and 120 min, cells were then fixed and stained with p65 antibody. Control cells were not subjected to any treatment. The images were collected with fluorescent laser scanning confocal microscope. Results are representative of three separate experiments. Arrows denote the expression of p65 antigen in the cytoplasm or nucleus, respectively.

activation by CRH reflects I $\kappa$ B degradation, I $\kappa$ B- $\alpha$  levels were determined after CRH addition by immunoblotting. As shown in Fig. 4, the CRH induced I $\kappa$ B- $\alpha$  degradation in keratinocytes in a time-dependent manner. Level of I $\kappa$ B- $\alpha$  decreased by 68% at 30 min and 50% at 60 min incubation. Thus, CRH-induced degradation of I $\kappa$ B- $\alpha$  preceded the increase in NF- $\kappa$ B DNA binding activity, which was maximal at 60 min (see Fig. 1 for comparison). As I $\kappa$ B- $\alpha$  has a  $\kappa$ B site in its promoter, activation of NF- $\kappa$ B results in up-regulation of I $\kappa$ B- $\alpha$  production (Li & Verma 2002). Indeed, at 120 min I $\kappa$ B- $\alpha$  returned to near basal levels, which reflects this latter process.


## Discussion

We have recently documented (Zbytek *et al.* 2003) that CRH inhibits NF- $\kappa$ B signaling in the immortalized line of HaCaT keratinocytes. In those cells, withdrawal of growth factors resulted in the enhancement of NF- $\kappa$ B signal and addition of CRH has markedly attenuated NF- $\kappa$ B activation. In the present study we have shown that CRH

stimulates NF- $\kappa$ B translocation from cytoplasm to nucleus followed by binding to specific DNA sequence and enhancement of  $\kappa$ B-driven transcription activity in the human normal epidermal keratinocytes derived from primary cultures.

Factors such as TNF- $\alpha$ , phorbol esters and interferon  $\gamma$  increase NF- $\kappa$ B activity in human keratinocytes (Chaturvedi *et al.* 1999, Qin *et al.* 2001). Signaling pathways triggered by these substances differ but they converge at the activation of I $\kappa$ B kinases which subsequently phosphorylate I $\kappa$ B proteins that are later ubiquitinated and degraded. This is followed by NF- $\kappa$ B release and translocation to nucleus. In contrast to HaCaT cells where NF- $\kappa$ B activation by growth factor removal and attenuation of this process by CRH was linked to I $\kappa$ B- $\beta$  degradation, in human primary keratinocytes CRH caused rapid I $\kappa$ B- $\alpha$  degradation. I $\kappa$ B- $\alpha$  is subsequently resynthesized due to the presence of NF- $\kappa$ B response element in the I $\kappa$ B- $\alpha$  gene promoter (Li & Verma 2002). Bands detected by the I $\kappa$ B- $\alpha$  specific antibody represent both unphosphorylated and phosphorylated forms. I $\kappa$ B- $\alpha$  phosphorylation occurs at Ser 32 and 36 at the amino terminus (Li & Verma 2002).

To further characterize CRH effects on NF- $\kappa$ B activity in the keratinocytes, we have subjected the cells to the combined treatment with phorbol ester and interferon  $\gamma$ , which are recognized stimulants of NF- $\kappa$ B activity (Chaturvedi *et al.* 1999, Quin *et al.* 2001). Although phorbol ester and interferon  $\gamma$  treatment resulted in the increase of NF- $\kappa$ B activity, CRH did not alter this response (Fig. 1B). Lack of signal modification may suggest that either protein kinase C (PKC) pathway (stimulated by phorbol esters) or Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway (stimulated by interferons) may be involved in signaling between CRH receptor and I $\kappa$ B kinases. Indeed, CRH may stimulate PKC pathway (reviewed in: Slominski *et al.* 2000c) and the JAK/STAT signaling pathway is involved



**Figure 4** CRH induces I $\kappa$ B- $\alpha$  degradation. Keratinocytes were grown in growth media and 100 nM CRH was then added for indicated time periods. Total cell lysates were analyzed by immunoblotting. Results are representative of three separate experiments.

in enhancement of transcription of POMC gene, which is a major target gene of CRH signal (Ray *et al.* 1998).

We have found that CRH treatment results in translocation of the p65 protein, increases binding activity by p50/p50 and p65/p50 dimers, and increases transcriptional activity of  $\kappa$ B-dependent reporter construct. NF- $\kappa$ B dimers containing p65 are generally considered to stimulate gene expression (Li & Verma 2002). This data is consistent with reported enhancement of HLA-DR and ICAM-1 expression in human primary keratinocytes and inhibition of proliferation of these cells (Quevedo *et al.* 2001). HLA-DR and ICAM-1 genes possess  $\kappa$ B binding sites (Li & Verma 2002). NF- $\kappa$ B activation in the keratinocytes results in growth arrest dependent on suppression of cyclin dependent kinase (cdk) 4 and upregulation of cdk inhibitor p21 (Dajee *et al.* 2003, Seitz *et al.* 2000).

CRH-induced NF- $\kappa$ B activation in human primary keratinocytes is consistent with reported CRH-induced NF- $\kappa$ B activation in the immune system (Zhao & Karalis 2002). Triggering the NF- $\kappa$ B pathway by CRH in keratinocytes is yet another argument supporting the existence of local epidermal regulatory circuits that are based on substances found in the nervous system (Slominski *et al.* 1998, 2000b, 2000c 2001). Because the skin has to react to noxious environmental stimuli it must be able to differentiate among them and respond accordingly in a localized and timely manner. Stressors such as ultraviolet light, bacteria or viruses are known to stimulate NF- $\kappa$ B activity. CRH may be one of the messengers that deliver information about noxious stimuli from cells that detect foreign antigens (e.g. Langerhans cells) to responders (e.g. lymphocytes or keratinocytes).

In summary, we have demonstrated for the first time that CRH can trigger the stress-related NF- $\kappa$ B pathway in human adult epidermal keratinocytes derived from primary cultures.

## Acknowledgements

The work was supported by National Institutes of Health grants CA 73753 (L M P), AR047079 (A S) and Johnson and Johnson Skin Research Training Grant (B Z). Confocal microscopy was performed on the equipment obtained through Shared Instrumentation Grant from National Center for Research Purposes at the National Institutes of Health (S10 RR13725-01) with the excellent technical assistance of Ms. Carolyn Matthews.

## References

Barker JN, Mitra RS, Griffiths CE, Dixit VM & Nickoloff BJ 1991 Keratinocytes as initiators of inflammation. *Lancet* **337** 211–214.  
 Chaturvedi V, Qin JZ, Denning MF, Choubey D, Diaz MO & Nickoloff BJ 1999 Apoptosis in proliferating, senescent, and immortalized keratinocytes. *Journal of Biological Chemistry* **274** 23358–23367.

Chrousos GP & Gold PW 1992 The concepts of stress and stress system disorders. *Journal of the American Medical Association* **267** 1244–1252.  
 Dajee M, Lazarov M, Zhang JY, Cai T, Green CL, Russell AJ, Marinkovich MP, Tao S, Lin Q, Kubo Y & Khavari PA 2003 NF- $\kappa$ B blockade and oncogenic Ras trigger invasive human epidermal neoplasia. *Nature* **421** 639–643.  
 Fazal N, Slominski A, Choudhry MA, Wei ET & Sayeed MM 1998 Effect of CRF and related peptides on calcium signaling in human and rodent melanoma cells. *FEBS Letters* **435** 187–190.  
 Freedberg IM, Tomic-Canic M, Komine M & Blumenberg M 2001 Keratins and the keratinocyte activation cycle. *Journal of Investigative Dermatology* **116** 633–640.  
 Hagan P, Poole S & Bristow AF 1992 Immunosuppressive activity of corticotropin-releasing factor. Inhibition of interleukin-1 and interleukin-6 production by human mononuclear cells. *Biochemical Journal* **281** 251–254.  
 Leu SJ & Singh VK 1992 Stimulation of interleukin-6 production by corticotropin-releasing factor. *Cellular Immunology* **143** 220–227.  
 Lezoualc'h F, Engert S, Berning B & Behl C 2002 Corticotropin-releasing hormone-mediated neuroprotection against oxidative stress is associated with the increased release of non-amyloidogenic amyloid  $\beta$  precursor protein and with the suppression of NF- $\kappa$ B. *Molecular Endocrinology* **14** 147–159.  
 Li Q & Verma IM 2002 NF- $\kappa$ B regulation in the immune system. *Nature Reviews. Immunology* **2** 725–734.  
 Mempel M, Voelcker V, Köllisch G, Plank C, Rad R, Gerhard Mi, Schnopp C, Fraunberger P, Walli AK, Ring J, Abeck D & Ollert M 2003 Toll-like receptor expression in human keratinocytes: nuclear factor- $\kappa$ B controlled gene activation by *Staphylococcus aureus* is toll-like receptor 2 but not toll-like receptor 4 or platelet activating factor receptor dependent. *Journal of Investigative Dermatology* **121** 1389–1396.  
 Pereda MP, Saucer J, Castro CP, Finkielman S, Stalla GK, Holsboer F & Arzt E 1995 Corticotropin-releasing hormone differentially modulates the interleukin-1 system according to the level of monocyte activation by endotoxin. *Endocrinology* **136** 5504–5510.  
 Pisarchik A & Slominski AT 2001 Alternative splicing of CRH-R1 receptors in human and mouse skin: identification of new variants and their differential expression. *FASEB Journal* **15** 2754–2756.  
 Quevedo ME, Slominski A, Pinto W, Wei E & Wortsman J 2001 Pleiotropic effects of corticotropin-releasing hormone on normal human skin keratinocytes. *In Vitro Cellular and Developmental Biology. Animal* **37** 50–54.  
 Qin JZ, Bacon P, Chaturvedi V & Nickoloff BJ 2001 Role of NF- $\kappa$ B activity in apoptotic response of keratinocytes mediated by interferon- $\gamma$ , tumor necrosis factor- $\alpha$ , and tumor-necrosis-factor-related apoptosis-inducing ligand. *Journal of Investigative Dermatology* **117** 898–907.  
 Ray DW, Ren SG & Melmed S 1998 Leukemia inhibitory factor regulates pro-opiomelanocortin transcription. *Annals of the New York Academy of Sciences* **840** 162–173.  
 Schallreuter KU 1997 Epidermal adrenergic signal transduction as part of the neuronal network in the human epidermis. *Journal of Investigative Dermatology Symposium Proceedings* **2** 37–40.  
 Singh VK 1989 Stimulatory effect of corticotropin-releasing neurohormone on human lymphocyte proliferation and interleukin-2 receptor expression. *Journal of Neuroimmunology* **23** 257–262.  
 Seitz CS, Deng H, Hinata K, Lin Q & Khavari PA 2000 Nuclear factor- $\kappa$ B subunits induce epithelial cell growth arrest. *Cancer Research* **60** 4085–4092.  
 Singh VK & Leu SC 1990 Enhancing effect of corticotropin-releasing neurohormone on the production of interleukin-1 and interleukin-2. *Neuroscience Letters* **120** 151–154.  
 Slominski AT, Botchkarev V, Choudhry M, Fazal N, Fechner K, Furkert J, Krause E, Roloff B, Sayeed M, Wei E *et al.* 1999

- Cutaneous expression of CRH and CRH-R. Is there a 'skin stress response system?' *Annals of the New York Academy of Sciences* **885** 287–311.
- Slominski A, Ermak G, Mazurkiewicz JE, Baker J & Wortsman J 1998 Characterization of corticotropin-releasing hormone (CRH) in human skin. *Journal of Clinical Endocrinology and Metabolism* **83** 1020–1024.
- Slominski AT, Roloff B, Zbytek B, Wei ET, Fechner K, Curry J & Wortsman J 2000a Corticotropin-releasing hormone and related peptides can act as bioregulatory factors in human keratinocytes. *In Vitro Cellular and Developmental Biology. Animal* **36** 211–216.
- Slominski A, Szczesniowski A & Wortsman J 2000b Liquid chromatography-mass spectrometry detection of corticotropin-releasing hormone and proopiomelanocortin-derived peptides in human skin. *Journal of Clinical Endocrinology and Metabolism* **85** 3582–3588.
- Slominski A & Wortsman J 2000 Neuroendocrinology of the skin. *Endocrine Reviews* **21** 457–487.
- Slominski A, Wortsman J, Luger T, Paus R & Salomon S 2000c Corticotropin-releasing hormone and proopiomelanocortin involvement in the cutaneous response to stress. *Physiological Reviews* **80** 979–1020.
- Slominski AT, Wortsman J, Pisarchik A, Zbytek B, Linton EA, Mazurkiewicz JE & Wei ET 2001 Cutaneous expression of corticotropin releasing hormone (CRH), urocortin, and CRH receptors. *FASEB Journal* **15** 1678–1693.
- Theoharides TC, Singh LK, Boucher W, Pang X, Letourneau R, Webster E & Chrousos G 1998 Corticotropin releasing hormone induces skin mast cell degranulation and increased vascular permeability, a possible explanation for its pro-inflammatory effects. *Endocrinology* **139** 403–413.
- Wiesner B, Roloff B, Fechner K & Slominski A 2003 Intracellular calcium measurements of single human skin cells after stimulation with corticotropin releasing factor and urocortin using confocal laser scanning microscopy. *Journal of Cell Science* **116** 1261–1268.
- Yang CH, Murti A, Pfeffer SR, Basu L, Kim JG & Pfeffer LM 2000 IFN  $\alpha/\beta$  promotes cell survival by activating NF- $\kappa$ B. *PNAS* **97** 13631–13636.
- Zbytek B, Mysliwski A, Slominski A, Wortsman J, Wei ET & Mysliwska J 2002 Corticotropin releasing hormone affects cytokine production in human HaCaT keratinocytes. *Life Sciences* **70** 1013–1021.
- Zbytek B, Pfeffer LM & Slominski AT 2003 Corticotropin releasing hormone inhibits nuclear factor- $\kappa$ B pathway in human HaCaT keratinocytes. *Journal of Investigative Dermatology* **121** 1496–1499.
- Zhao J & Karalis K 2002 Regulation of nuclear factor- $\kappa$ B by corticotropin releasing hormone in mouse thymocytes. *Molecular Endocrinology* **16** 2561–2570.